Alzheimer’s Society backs drug companies against NICE ruling

Posted on January 1st, by editor in Caring Times. No Comments

Two drug companies – Eisai Ltd, the licence holder of anti-dementia drug Aricept and Pfizer Ltd, Eisai’s co-promotion partner, have applied to the High Court for permission to request a Judicial Review of the process by which the National Institute for Health and Clinical Excellence (NICE) reached its decision to ban anti dementia medicines for NHS patients with newly diagnosed mild Alzheimer’s disease. The drug companies will be supported by other other parties, notably the Alzheimer’s Society, as co-claimants. Eisai wrote to NICE in November calling on the body to withdraw its Final Appraisal Document (FAD) and disclose a fully transparent working version of the model used in the calculation of cost-effectiveness and develop a new FAD using rational clinical assumptions and also to prevent discrimination against certain vulnerable groups of patients. NICE has refused to make any changes to the FAD or to disclose the requested model. As a result Eisai and Pfizer, have now applied for permission to pr

Comments are closed.

Latest blog posts

Inconstant gardeners

By Caring Times editor GEOFF HODGSON

Last Saturday was fine and dry so I managed to put in a few hours on our allotment. Not...

When the chips go down . . .

By Caring Times editor GEOFF HODGSON

I have heard people say they couldn’t get by without their smartphone, and I suppose this must be true...

Loneliness behind the front doors

By Guest Blogger KEITH LEWIN

Last week SCIE issued its monthly ‘Briefing for Commissioners’, its focus is on social isolation which it correctly says “can...